Rescuing drug discovery: In vivo systems pathology and systems pharmacology

article

Greef, J. van der

McBurney, R.N.
The pharmaceutical industry is currently beleaguered by close scrutiny from the financial community, regulators and the general public. Productivity, in terms of new drug approvals, has generally been falling for almost a decade and the safety of a number of highly successful drugs has recently been brought into question. Here, we discuss whether taking an in vivo systems approach to drug discovery and development could be the paradigm shift that rescues the industry.
Topics




























































Analytical research5' methoxyhydnocarpinBerberineBiological markerGinseng extractHerbaceous agentHypericum extractParoxetineUnclassified drugBioinformaticsCardiovascular diseaseClinical trialCost benefit analysisCost controlCost effectiveness analysisData baseDepressionDrug approvalDrug designDrug efficacyDrug indicationDrug industryDrug informationDrug marketingDrug researchDrug responseDrug safetyDrug screeningDrug targetingGrowth inhibitionHealth careHealth care costHealth programHumanIn vivo studyNon insulin dependent diabetes mellitusNonhumanPatient compliancePredictionPrescriptionPriority journalProductivityQuantitative analysisStandardSystem analysisValidation processAnimalDiagnosisEconomicsMass communicationReviewAnimalsCost-Benefit AnalysisDiagnosisDiffusion of InnovationDrug ApprovalDrug DesignDrug EvaluationDrug Evaluation, PreclinicalDrug IndustryHumans
TNO Identifier
238972
Repository link
https://resolver.tno.nl/uuid:964742a4-50fc-45b5-97d4-158693fa44cc
ISSN
14741776
Source
Nature Reviews Drug Discovery, 4(12), pp. 961-967.
Pages
961-967
Files
To receive the publication files, please send an e-mail request to TNO Repository.